World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision.

Department of Psychiatry and Psychotherapy, University of Gottingen, Gottingen, Germany.
The World Journal of Biological Psychiatry (Impact Factor: 4.23). 02/2008; 9(4):248-312. DOI: 10.1080/15622970802465807
Source: PubMed

ABSTRACT In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, World J Biol Psychiatry 3:171), recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo- or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to evaluate the effectiveness of acceptance and commitment therapy (ACT) in treating obsessive compulsive disorder (OCD). In a single-subject experiment trial, the treatment process was carried out on a 39-year old male subject. The patient satisfied the DSM-IV-TR criteria for OCD and was assessed for pre-duration and post treatment. The scales used in this study included: The Yale-Brown Obsessive Compulsive Scale(Y-BOCS), Beck Depression Inventory-II-second edition (BDI-II), and Beck Anxiety Inventory (BAI). In addition, all scales were again completed by the subject at 1-month, 3-months, and 6-months follow-ups. The treatment led to reductions in symptoms of OCD, depression and anxiety. Gains were maintained at follow-ups. The treatment approach appears to be effective in the treatment of OCD.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Benzodiazepines (BDZs) continue to be shrouded in controversy, mainly because of dependence associated with their long-term use and some of their side effects. Despite treatment recommendations favoring newer antidepressants, BDZs are still commonly prescribed for anxiety and related disorders. Recent studies have demonstrated that long-term use of BDZs for these conditions can be effective and safe and that BDZs can be combined with psychological therapy and antidepressants to produce optimal outcomes. Such findings, along with a failure to convincingly demonstrate the overall superiority of alternative pharmacotherapy for anxiety and related disorders, have given an impetus to a reconsideration of the role of BDZs. This article reviews BDZs and other pharmacotherapy options for anxiety and related disorders and suggests that treatment guidelines should acknowledge that BDZs can be used as first-line, long-term pharmacological treatment for panic disorder, generalized anxiety disorder and social anxiety disorder.
    Expert Review of Neurotherapeutics 09/2014; 14(11). DOI:10.1586/14737175.2014.963057 · 2.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The underlying brain basis of nonclinical depressive symptoms (nCDSs) is largely unknown. Recently, the seed-based functional connectivity (FC) approach for analyzing resting-state fMRI (rs-fMRI) data has been increasingly used to explore the neural basis of depressive disorders. Other than common seed-based FC method using an a priori seed region, we conducted FC analysis based on regions with altered spontaneous activity revealed by the fractional amplitude of low-frequency fluctuations (fALFF) approach. The aim of the present study was to provide novel insight in the underlying mechanism of nCDSs in college students. A total number of 1105 college students were recruited to participant in a survey for assessing depressive symptoms. Subsequently, 17 individuals with nCDSs and 20 healthy controls (HCs) were enrolled to perform MR studies. Alternations of fALFF were identified in the right superior parietal lobule (SPL) and left lingual gyrus, both of which were used as ROIs for further FC analysis. With right SPL, compare with HCs, subjects with nCDSs showed reduced FCs in the bilateral dorsal lateral prefrontal cortex (DLPFC), left inferior frontal gurus (IFG), left premotor cortex (PMC), DMN network [i.e., bilateral precuneus, posterior cingulate cortex (PCC), right supramarginal gyrus (SMG), right parahippocampal gyrus (PHG), bilateral inferior temporal gurus (ITG)] and left cerebellum posterior lobe (CPL). In addition, increased FCs were observed between the left lingual gyrus and right fusiform gyrus as well as in the left precuneus. Our results indicate the abnormalities of spontaneous activity in the right SPL and left lingual gyrus and their corresponding dysfunction of the brain circuits might be related to the pathophysiology of nCDSs.
    PLoS ONE 12/2014; 9(12):e114603. DOI:10.1371/journal.pone.0114603 · 3.53 Impact Factor

Full-text (2 Sources)

Available from
May 19, 2014